This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Adefovir
Accession Number
DB13868
Type
Small Molecule
Groups
Investigational
Description
Not Available
Structure
Thumb
Synonyms
  • 9-(2-(phosphonomethoxy)ethyl)adenine
  • 9-(2-phosphonylmethoxyethyl)adenine
  • Adéfovir
  • Adefovir
  • Adefovirum
External IDs
GS 0393 / GS-0393
Categories
UNII
6GQP90I798
CAS number
106941-25-7
Weight
Average: 273.1857
Monoisotopic: 273.062690409
Chemical Formula
C8H12N5O4P
InChI Key
SUPKOOSCJHTBAH-UHFFFAOYSA-N
InChI
InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)
IUPAC Name
{[2-(6-amino-9H-purin-9-yl)ethoxy]methyl}phosphonic acid
SMILES
NC1=C2N=CN(CCOCP(O)(O)=O)C2=NC=N1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
ADNA polymerase/reverse transcriptase
inhibitor
HBV-D
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAdefovir may decrease the excretion rate of Abacavir which could result in a higher serum level.
AcarboseAdefovir may decrease the excretion rate of Acarbose which could result in a higher serum level.
AceclofenacAdefovir may decrease the excretion rate of Aceclofenac which could result in a higher serum level.
AcemetacinThe risk or severity of nephrotoxicity can be increased when Acemetacin is combined with Adefovir.
AcetaminophenAdefovir may decrease the excretion rate of Acetaminophen which could result in a higher serum level.
Acetylsalicylic acidThe risk or severity of nephrotoxicity can be increased when Acetylsalicylic acid is combined with Adefovir.
AclidiniumAdefovir may decrease the excretion rate of Aclidinium which could result in a higher serum level.
AcrivastineAdefovir may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAdefovir may decrease the excretion rate of Acyclovir which could result in a higher serum level.
Adefovir dipivoxilThe risk or severity of nephrotoxicity can be increased when Adefovir dipivoxil is combined with Adefovir.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
ChEBI
2469
HET
5HG
Wikipedia
Adefovir
PDB Entries
2g1a

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceDrug Interaction Potentiation1
1CompletedTreatmentHepatitis B Chronic Infection1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentHBV (Hepatitis B Virus) / Hepatitis / Viral Hepatitis B1
2CompletedTreatmentHepatitis B Chronic Infection2
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Viral Hepatitis B1
2TerminatedTreatmentHepatitis B Chronic Infection1
2Unknown StatusTreatmentHepatitis B Virus (HBV) / Hepatocellular,Carcinoma1
3CompletedOtherHepatitis B Chronic Infection1
3CompletedTreatmentDisease, Chronic / Viral Hepatitis B1
3CompletedTreatmentHepatitis B Chronic Infection1
3CompletedTreatmentViral Hepatitis B1
3TerminatedTreatmentHepatitis B Chronic Infection1
3TerminatedTreatmentHepatitis, Chronic / Viral Hepatitis B2
3Unknown StatusTreatmentHepatitis B Chronic Infection1
4Active Not RecruitingTreatmentHepatitis B Chronic Infection1
4Active Not RecruitingTreatmentViral Hepatitis B1
4CompletedTreatmentCompensated Chronic Hepatitis B1
4CompletedTreatmentHepatitis B Associated Hepatocellular Carcinoma1
4CompletedTreatmentHepatitis B Chronic Infection5
4RecruitingTreatmentHepatic Carcinoma / Hepatitis B Chronic Infection1
4RecruitingTreatmentHepatitis B Chronic Infection1
4TerminatedTreatmentHepatitis B Chronic Infection1
4Unknown StatusTreatmentHBV-related Liver Cirrhosis2
4Unknown StatusTreatmentHepatitis B Chronic Infection2
4Unknown StatusTreatmentHepatitis B Chronic Infection / Inadequate Response / Nucleos(t)Ide Analogues Treatment1
4Unknown StatusTreatmentViral Hepatitis B1
4WithdrawnTreatmentHepatitis B Chronic Infection1
Not AvailableCompletedNot AvailableViral Hepatitis B1
Not AvailableUnknown StatusPreventionTransplantation, Liver / Viral Hepatitis B1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.02 mg/mLALOGPS
logP-1.8ALOGPS
logP-4.5ChemAxon
logS-2.1ALOGPS
pKa (Strongest Acidic)1.35ChemAxon
pKa (Strongest Basic)5.12ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count8ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area136.38 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity63.12 m3·mol-1ChemAxon
Polarizability23.56 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Imidazopyrimidines
Sub Class
Purines and purine derivatives
Direct Parent
6-aminopurines
Alternative Parents
Aminopyrimidines and derivatives / N-substituted imidazoles / Imidolactams / Organic phosphonic acids / Heteroaromatic compounds / Azacyclic compounds / Primary amines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds
show 2 more
Substituents
6-aminopurine / Aminopyrimidine / N-substituted imidazole / Pyrimidine / Imidolactam / Azole / Imidazole / Organophosphonic acid / Organophosphonic acid derivative / Heteroaromatic compound
show 12 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
HBV-D
Pharmacological action
Yes
Actions
Inhibitor
General Function
Rna-dna hybrid ribonuclease activity
Specific Function
Multifunctional enzyme that converts the viral RNA genome into dsDNA in viral cytoplasmic capsids. This enzyme displays a DNA polymerase activity that can copy either DNA or RNA templates, and a ri...
Gene Name
P
Uniprot ID
P24024
Uniprot Name
Protein P
Molecular Weight
93588.765 Da
References
  1. Kock J, Baumert TF, Delaney WE 4th, Blum HE, von Weizsacker F: Inhibitory effect of adefovir and lamivudine on the initiation of hepatitis B virus infection in primary tupaia hepatocytes. Hepatology. 2003 Dec;38(6):1410-8. [PubMed:14647052]

Drug created on July 06, 2017 20:58 / Updated on January 05, 2018 13:27